Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

Joanna M Wardlaw, Veronica Murray, Eivind Berge, Gregory del Zoppo, Peter Sandercock, Richard L Lindley, Geoff Cohen

Research output: Contribution to journalArticlepeer-review

Abstract

Recombinant tissue plasminogen activator (rt-PA, alteplase) improved functional outcome in patients treated soon after acute ischaemic stroke in randomised trials, but licensing is restrictive and use varies widely. The IST-3 trial adds substantial new data. We therefore assessed all the evidence from randomised trials for rt-PA in acute ischaemic stroke in an updated systematic review and meta-analysis.
Original languageEnglish
Pages (from-to)2364-72
Number of pages9
JournalThe Lancet
Volume379
Issue number9834
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this